A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics in vivo.

Bibliographic Details
Title: A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics in vivo.
Authors: Zhong, Guocai, Wang, Haimin, He, Wenhui, Li, Yujun, Mou, Huihui, Tickner, Zachary J., Tran, Mai H., Ou, Tianling, Yin, Yiming, Diao, Huitian, Farzan, Michael
Source: Nature Biotechnology; Feb2020, Vol. 38 Issue 2, p169-175, 7p, 4 Graphs
Abstract: Widespread use of gene therapy technologies is limited in part by the lack of small genetic switches with wide dynamic ranges that control transgene expression without the requirement of additional protein components1–5. In this study, we engineered a class of type III hammerhead ribozymes to develop RNA switches that are highly efficient at cis-cleaving mammalian mRNAs and showed that they can be tightly regulated by a steric-blocking antisense oligonucleotide. Our variant ribozymes enabled in vivo regulation of adeno-associated virus (AAV)-delivered transgenes, allowing dose-dependent and up to 223-fold regulation of protein expression over at least 43 weeks. To test the potential of these reversible on-switches in gene therapy for anemia of chronic kidney disease6, we demonstrated regulated expression of physiological levels of erythropoietin with a well-tolerated dose of the inducer oligonucleotide. These small, modular and efficient RNA switches may improve the safety and efficacy of gene therapies and broaden their use. In vivo control of expression levels of AAV-delivered genes is enabled by an engineered RNA switch. [ABSTRACT FROM AUTHOR]
Copyright of Nature Biotechnology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
More Details
ISSN:10870156
DOI:10.1038/s41587-019-0357-y
Published in:Nature Biotechnology
Language:English